Novel personalized vaccine immunotherapies for cancer

Metaclipse Therapeutics is pioneering the development of innovative immunotherapy platforms aimed at treating cancer and preventing infectious diseases. Their lead product, Membrex™, is an autologous immunotherapy that combines neoantigens and tumor-associated antigens derived from a patient's own tumor with proprietary biological adjuvants. This approach is designed to enhance the immune response, particularly in cases resistant to immune checkpoint inhibitors (ICIs). Membrex™ is tailored to each patient, utilizing membrane vesicles modified with immunostimulatory proteins to deliver a comprehensive array of tumor antigens, thereby addressing the heterogeneity of cancer. The company is preparing to initiate Phase 1 clinical trials for Membrex™ in advanced cancers, including triple negative breast cancer and head and neck squamous cell carcinoma, in 2024.

In addition to Membrex™, Metaclipse is developing the VaxRex™ vaccine platform, which utilizes virus-like particles (VLPs) modified with membrane-anchored biological adjuvants. This platform aims to elicit strong immune responses against infectious diseases, particularly in vulnerable populations such as the elderly and immunocompromised individuals. VaxRex™ is designed to provide broad applicability against various enveloped viruses, including influenza and SARS-CoV-2, while ensuring rapid production and a favorable safety profile. Both platforms leverage the unique properties of membrane-bound biological adjuvants to enhance immune activation, with the goal of commercializing these therapies through partnerships with major pharmaceutical companies after demonstrating their safety and efficacy.

United States

Metaclipse Therapeutics is a preclinical stage biotech company developing novel cancer therapies that are tailored to each patient and their specific tumor. The Company’s first ‘personalized’ cancer therapy is for triple negative metastatic breast cancer. Metaclipse intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing their safety and effectiveness in early clinical trials by year-end 2019.

Metaclipse Therapeutics

Company Details